
Systemic Therapies Are Now Preferred in Some Patients With HER2+ Breast Cancer Brain Metastases
The high level of intracranial activity seen with novel HER2-targeted therapies has created a new paradigm that defers local therapy in favor of systemic options to treat small asymptomatic brain metastases in patients with metastatic breast cancer, …